Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IXIARO · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| >14 months to <2 years | ACTIVE_COMPARATOR | IXIARO 0.25 ml i.m. (milliliter, intramuscular) |
| >3 years - <18 years | ACTIVE_COMPARATOR | IXIARO 0.5 ml i.m (milliliter, intramuscular) |
| Name | Type | Description |
|---|---|---|
| IXIARO | BIOLOGICAL | 0.25 ml i.m. (milliliter, intramuscular) |
Inclusion Criteria: * Children and adolescents who have completed study IC51-323 and received both IXIARO vaccinations according to protocol. * Children who have received the dose confirmed for their age group. * Male or female healthy children and adolescents aged ≥9 months to \<17 years and 7 mon...
IXIARO is a vaccine used for Japanese Encephalitis, a viral infection of the brain transmitted by mosquitoes. It is being developed for use in pediatric populations in endemic countries, with a completed Phase 3 trial in the Philippines involving 300 participants aged 9 months and older.
IXIARO is developed by Valneva SE, a biopharmaceutical company traded on the stock exchange under the ticker VALN. The company conducted a Phase 3 clinical trial for the vaccine in a Japanese Encephalitis-endemic country.
IXIARO is in Phase 3 clinical development. A Phase 3 trial, NCT01296360, has been completed. The vaccine is investigational and not yet approved for use, as it is still undergoing clinical evaluation for pediatric populations.
IXIARO has one completed Phase 3 clinical trial, NCT01296360, titled "Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country." The trial enrolled 300 participants in the Philippines and was active-controlled, though not double-blinded.
IXIARO is a vaccine specifically designed to prevent Japanese Encephalitis, a mosquito-borne viral disease. It is being studied in pediatric populations in endemic regions, with a completed Phase 3 trial demonstrating its investigational use for this indication.